Sinonasal teratocarcinosarcoma treated with surgery followed by volumetric modulated radiotherapy: a case report with review of literature

Tandon, Sarthak; Gairola, Munish; Ahlawat, Parveen; Sharma, Kanika; Barik, Soumitra; Sachdeva, N.; Pasricha, Sunil; Shenoy, Apeksha

doi:10.3857/roj.2018.00304

Cited by 4 publications

(3 citation statements)

References 22 publications

(35 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 31 The local recurrence rate ranges from 25% to 55%. 5 , 27 – 29 , 32 , 33 Thus, follow-up nasal endoscopy and/or positron-emission tomography-CT is essential to screen for early recurrence. Our patient received surgery combined with chemoradiotherapy and was followed-up regularly for 5 years without any recurrence or metastasis.…”

Section: Discussionmentioning

confidence: 99%

Sinonasal teratocarcinosarcoma: a case report and literature review

et al. 2020

View full text Add to dashboard Cite

Background Sinonasal teratocarcinosarcoma (SNTCS) is a highly invasive malignant tumor most frequently found in the nasal cavity and paranasal sinuses. As a result, it can be confused with other sinonasal tumors. In addition, SNTCS progresses rapidly and often infiltrates other tissues or organs in the early phase, resulting in poor patient prognosis. The objective of this article was to report the case of a patient with SNTCS and discuss the management strategy. Furthermore, we conducted a literature review for SNTCS and summarized the findings from 107 cases. Case presentation: Here, we report a 47-year-old man diagnosed with SNTCS and treated with radiochemotherapy after an initial operation. After follow-up for 5 years, no tumor recurrence was observed. Conclusions As SNTCS progresses rapidly, early diagnosis and surgical treatment combined with radiochemotherapy can improve patient survival.

show abstract

Section: Discussionmentioning

confidence: 99%

Sinonasal teratocarcinosarcoma: a case report and literature review

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Although there are no official guidelines, the most common treatment strategy currently used for TCS is a bimodal therapy consisting of radical surgical resection with adjuvant radiotherapy, which is the strategy selected in 52% to 62% of cases. 6,7,42 The second most common management option is a trimodal approach combining surgery with adjuvant chemotherapy and focused radiation therapy, which has been used in 28% of cases. 7 This trimodal strategy appears to be the optimal choice, as it has shown the highest survival and lowest recurrence rates, as well as a significantly delayed time to death compared with bimodality or single surgical options.…”

Section: Treatment and Prognosismentioning

confidence: 99%

Teratocarcinosarcoma of the head and neck: Clinicopathologic review of a rare entity

AL-Zaidi

2023

Rare Tumors

View full text Add to dashboard Cite

Teratocarcinosarcoma is a rare, highly aggressive malignancy of the head and neck, characterized by multiphenotypic and triphasic growth of epithelial, mesenchymal, and primitive neuroepithelial elements. Owing to its rarity and morphological heterogeneity, as well as the lack of experience with this neoplasm, teratocarcinosarcoma is often misdiagnosed, particularly in small biopsy samples when only some of the elements are identified, thus leading to delayed management. Aggressive clinical behavior and poor survival outcomes, necessitate an accurate diagnosis and appropriate treatment. This review describes the main demographic and clinicopathological features of teratocarcinosarcoma, with an emphasis on the recent advances that have attempted to identify the molecular signature of this neoplasm.

show abstract

“…Histologically they are heterogeneous lesions characterized by cells of different embryonic derivation (ectodermal, mesodermal and endodermal), in multiple degrees of differentiation 4 . The most widely used therapeutic approach is a combination of surgery and adjuvant intensity modulated radiotherapy (IMRT), but there are no official guidelines or consensus 7 . As an alternative to IMRT, proton beam therapy (PBT) is nowadays used to treat several head and neck tumors.…”

Section: Introductionmentioning

confidence: 99%

Sinonasal teratocarcinosarcoma treated with surgery and proton beam therapy: clinical, histological aspects and differential diagnosis of a new case

et al. 2021

View full text Add to dashboard Cite

Summary Sinonasal teratocarcinosarcoma is a rare aggressive malignant tumor with a primary setting involving the nasal cavity followed by the ethmoid sinus and maxillary sinus. It accounts for approximately 3% of all head and neck cancers and less than 1% of all tumors. Nasal obstruction, recurrent epistaxis and headache represent the typical clinical presentation. Imaging shows the presence of a mass in the nasal cavity. The treatment usually consists of surgery and adjuvant intensity modulated radiotherapy. The rarity and the variability of the histological features make its diagnosis particularly difficult. In this paper, we report a case of sinonasal teratocarcinosarcoma in a 62-year-old male treated with a multidisciplinary approach. As an alternative to intensity modulated radiotherapy, we proposed proton beam therapy for the first time. The patient benefited from the new and personalized protocol that provided excellent results and few adverse effects. At 45 months follow-up there is no evidence of relapse and the patient is in good health.

show abstract

Sinonasal teratocarcinosarcoma treated with surgery followed by volumetric modulated radiotherapy: a case report with review of literature

Cited by 4 publications

References 22 publications

Sinonasal teratocarcinosarcoma: a case report and literature review

Sinonasal teratocarcinosarcoma: a case report and literature review

Teratocarcinosarcoma of the head and neck: Clinicopathologic review of a rare entity

Sinonasal teratocarcinosarcoma treated with surgery and proton beam therapy: clinical, histological aspects and differential diagnosis of a new case

Contact Info

Product

Resources

About